Reporting Groups

	Description
XIENCE V® EECSS	XIENCE V® Everolimus Eluting Coronary Stent System
TAXUS® EXPRESS2™ ECSS	TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System. 1 patient randomized never signed consent, therefore no data collected. Taxus analysis group = 332.

Baseline Measures

	XIENCE V® EECSS	TAXUS® EXPRESS2™ ECSS	Total
Number of Participants   [units: participants]	669	333	1002
Age[1] [units: participants]
<=18 years	0	0	0
Between 18 and 65 years	376	191	567
>=65 years	293	141	434
Age[2] [units: years] Mean ± Standard Deviation	63.23 ± 10.53	62.80 ± 10.24	63.08 ± 10.43
Gender[3] [units: participants]
Female	200	114	314
Male	469	218	687
Region of Enrollment[4] [units: participants]
United States	669	333	1002

1.  Primary:

Primary Endpoint: In-segment Late Loss (LL)   [ 240 days ]

2.  Secondary:

Major Secondary Endpoint: Ischemia Driven Target Vessel Failure (ID-TVF)   [ 270 days ]

3.  Secondary:

Target Vessel Failure (TVF)   [ 30 days ]

4.  Secondary:

Target Vessel Failure (TVF)   [ 180 days ]

5.  Secondary:

Target Vessel Failure (TVF)   [ 1 year ]

6.  Secondary:

Target Vessel Failure (TVF)   [ 2 year ]

7.  Secondary:

Ischemia Driven Target Lesion Revascularization (ID-TLR)   [ 30 days ]

8.  Secondary:

Ischemia Driven Target Lesion Revascularization (ID-TLR)   [ 180 days ]

9.  Secondary:

Ischemia Driven Target Lesion Revascularization (ID-TLR)   [ 270 days ]

10.  Secondary:

Ischemia Driven Target Lesion Revascularization (ID-TLR)   [ 1 years ]

11.  Secondary:

Ischemia Driven Target Lesion Revascularization (ID-TLR)   [ 2 years ]

12.  Secondary:

Ischemia Driven Target Vessel Revascularization (ID-TVR)   [ 30 days ]

13.  Secondary:

Ischemia Driven Target Vessel Revascularization (ID-TVR)   [ 180 days ]

14.  Secondary:

Ischemia Driven Target Vessel Revascularization (ID-TVR)   [ 270 days ]

15.  Secondary:

Ischemia Driven Target Vessel Revascularization (ID-TVR)   [ 1 year ]

16.  Secondary:

Ischemia Drive Target Vessel Revascularization (ID-TVR)   [ 2 years ]

17.  Secondary:

Ischemia Driven Major Adverse Cardiac Event (MACE)   [ 30 days ]

18.  Secondary:

Ischemia Driven Major Adverse Cardiac Event (MACE)   [ 180 days ]

19.  Secondary:

Ischemia Driven Major Adverse Cardiac Event (MACE)   [ 270 days ]

20.  Secondary:

Ischemia Driven Major Adverse Cardiac Event (MACE)   [ 1 year ]

21.  Secondary:

Ischemia Driven Major Adverse Cardiac Event(MACE)   [ 2 years ]

22.  Secondary:

In-stent % Angiographic Binary Restenosis (% ABR) Rate   [ at 240 days ]

23.  Secondary:

In-segment % Angiographic Binary Restenosis (% ABR) Rate   [ 240 days ]

24.  Secondary:

Persisting Incomplete Stent Apposition, Late-acquired Incomplete Stent Apposition, Aneurysm, Thrombosis, and Persisting Dissection   [ at 240 days ]

25.  Secondary:

Acute Success: Clinical Device   [ In-hospital ]

26.  Secondary:

Acute Success: Clinical Procedure   [ In-hospital ]

27.  Secondary:

Proximal Late Loss   [ at 240 days ]

28.  Secondary:

Distal Late Loss   [ 240 days ]

29.  Secondary:

In-stent Late Loss   [ at 240 days ]

30.  Secondary:

% Volume Obstruction (% VO)   [ at 240 days ]

31.  Secondary:

In-stent % Diameter Stenosis (% DS)   [ at 240 days ]

32.  Secondary:

In-segment % Diameter Stenosis (% DS)   [ 240 days ]